Skip to main content

Table 3 corrected P-values for Sick leaves, Total number of exacerbation events and Mean FEV1 (litres)

From: Correction to: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences

 

Anti-IL5/IL5R (reslizumab, mepolizumab, benralizumab)

N = 42

 

Anti-IgE (omalizumab)

N = 22

 
 

Baseline

Change

P

Baseline

Change

P

Sick leaves **

0.93 (0–6. SD 1.72)

−0.58 (−6–6. SD 1.86)

0.037

0.59 (0–4. SD 1.03)

−0.14 (−3–11. SD 1.18)

0.602

Total number of exacerbation events ***

7.57 (1–26. SD 5.59)

−4.43 (−22–13. SD 6.24)

4.79 e− 05

4.68 (0–11. SD 3.40)

−1.50 (− 7–21. SD 5.55)

0.006

Mean FEV1 (litres)

2.27 (1.0–4.2. SD 0.78)

0.17 (− 0.5–1.3. SD 0.41)

0.317

2.83 (1.5–4.2. SD 0.86)

0.05 (− 0.6–1.3. SD 0.54)

0.720

  1. ** Number due to asthma during the last 12 months
  2. *** defined as the sum of courses of oral glucocorticoid and antimicrobial drugs, sick leaves, hospitalisations and emergency room visits due to asthma during the last 12 months